Kim NH, et al. - Whether coexistence of metabolic syndrome (MS) and chronic hepatitis B (CHB) affects the long-term prognosis of CHB patients with oral nucleos(t)ide analogues (NUCs) treatment was evaluated in this analysis. From January 2006 to March 2016, a retrospective data analysis was performed for a total of 587 CHB patients who began oral NUCs treatment for the first time in the institution. The study findings suggested that MS was an independent determinant of poor prognosis in CHB patients receiving oral NUCs treatment.